All In Biotech

Drug Trial Radar · NCT07613684

Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants

Phase 1 Study of Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Dec 20, 2024

Primary completion

Oct 9, 2025

Study completion Oct 9, 2025

Sponsor

Lead sponsor
Epirium Bio Inc.Industry
Sponsor type
Industry
First posted
May 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study will consist of 2 parts, Study Parts 1 (1a: single ascending dose \[SAD\] Phase; and 1b: Food Effect Phase) and Part 2 (multiple ascending dose \[MAD\] Phase). The SAD and MAD phases will evaluate separately non-elderly (≥ 18 to ≤ 65 years of age) and elderly (\> 65 to ≤75 years of age) healthy adult subjects.

Conditions

  • Healthy Volunteers

Interventions

  • MF-300 SADDrug

    oral capsule at doses of 75mg, 125 mg, 250 mg, 500 mg, or 800 mg

  • PlaceboDrug

    matching placebo oral capsule

  • MF-300 Food EffectDrug

    oral capsule at a dose of 500 mg

  • MF-300 MADDrug

    oral capsule at doses of 75mg, 125 mg, or 200 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with treatment-emergent adverse events (TEAEs)Time frame: From admission on Day -1 to the Follow-up End of Study Visit (Day 7 for Part 1a, Day 13 for Part 1b, and Day 11 for Part 2)
  2. Proportion of participants with serious adverse events (SAEs)Time frame: From admission on Day -1 to the Follow-up End of Study Visit (Day 7 for Part 1a, Day 13 for Part 1b, and Day 11 for Part 2)
  3. Proportion of participants with any TEAE leading to premature discontinuation of study interventionTime frame: From admission on Day -1 to the Follow-up End of Study Visit (Day 7 for Part 1a, Day 13 for Part 1b, and Day 11 for Part 2)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site 102

    Marlton, New Jersey

  • Site 101

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.